Skip to content

midazolam / fentanyl combined in EBUS-TBNA

Randomized double blinded phase II trial of midazolam and midazolam / fentanyl combined in endobronchial ultrasonic-guided transbronchial needle aspiration (EBUS-TBNA) (KURM007) - midazolam / fentanyl in EBUS-TBNA

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs051210131
Enrollment
98
Registered
2021-12-10
Start date
2021-12-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer, Mediastinal tumor, Mediastinal lymphadenopathy

Interventions

Midazolam group Placebo 3 mL+ midazolam 2 mg Midazolam + fentanyl group fentanyl 30 microg /3 ml + midazolam 2 mg Is intravenously administered immediately before the start of respiratory endoscopy

Sponsors

Tachihara Motoko
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) over20 years old (2) EBUS-TBNA is scheduled to be performed for the purpose of biopsy of mediastinal lesions. (3) Document consent can be obtained by the patient regarding participation in this study

Exclusion criteria

Exclusion criteria: (1) drug hypersensitivity constitution such as allergies to the drugs used in this study. (2) Have acute narrow-angle glaucoma (3) Have myasthenia gravis (4) Have uncontrollable bronchial asthma (5) Being in a spastic state (6) Taking HIV protease inhibitor or nalmefene (7) The use of muscle relaxants is contraindicated (8) Prone to respiratory depression such as coma due to head injury, brain tumor, etc. (9) Taking opioids (10) Others who are judged to be inappropriate by the person in charge of this test

Design outcomes

Primary

MeasureTime frame
The rate of patients who meet all of the following during bronchoscopy 1) The MOAA/S scale 3-4 or BIS level 70-80 is reached as a sufficient sedation depth 2) As an evaluation of good sedative effect, the number of additions of midazolam + fentanyl/placebo within 30 minutes after the start of the test 2 times or less 3) Number of punctures 3 times or more as an index to complete the examination

Secondary

MeasureTime frame
1) The rate of patients who meet all of the following during bronchoscopy 1.The MOAA/S scale 3-4 or BIS level 70-80 is reached as a sufficient sedation depth 2. As an evaluation of good sedative effect, the number of additions of midazolam + fentanyl/placebo within 30 minutes after the start of the test 3 times or less 3. Number of punctures 3 times or more as an index to complete the examination 2)VAS value indicating the degree of pain including physical pain and mental pain during bronchoscopy 3) Dosage of lidocaine, midazolam, and fentanyl 4) MOAA / S scale, SpO2, oxygen requirement, respiratory rate, blood pressure, pulse rate, complications 5) Whether or not flumazenil is used 6) adverse events 7) Examiner satisfaction 8) Diagnosis rate, test time, test interruption rate and interruption time, BIS value

Contacts

Public ContactMotoko Tachihara

Kobe University Hospital

mt0318@med.kobe-u.ac.jp+81-783825660

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026